Barclays downgraded Celanese to Equal Weight from Overweight with an unchanged price target of $170 as part of a Q1 earnings preview for the chemicals and packaging group. A modest recovery emerging, but this is against valuations at multi-year highs, the analyst tells investors in a research note. The firm thinks the “early cycle playbook” continues to support the space but it “getting more selective” in its stock picks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CE:
- Celanese price target raised to $195 from $180 at Wells Fargo
- Celanese, Secarna Pharmaceuticals enter RNA research collaboration
- Celanese, Secarna in RNA research collaboratioon for ASO therapies
- William M. Brown Exits Celanese Board for 3M CEO Role
- Celanese Corp Welcomes Timothy Go to Expanded Board
